CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 79 enrolled
Drug / intervention
tiotropium bromide +1 moredrug
Likely dose
tiotropium bromide 18 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01662986
NCT01662986Phase 4Completed
CompareCT.gov

A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 2)

Boehringer Ingelheim·interventional·Posted Aug 13, 2012·Updated Oct 17, 2018

In Brief

A Phase 4 clinical trial evaluating tiotropium bromide and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 79 participants across 50 sites.

Detailed Summary

A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2012
Enrollment StartAug 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.9 years ago

Interventions

tiotropium bromidedrug

18 mcg once a day (QD)

Placebodrug

Once a day (QD)